Evidence map›Paper›PMID 35790449›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2022

[Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2].

H Fan, K Liu, B Hong, S He, P Han, M Li, S Wang, Y Tong

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

H FanCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
K LiuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
B HongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
S HeCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
P HanCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
M LiCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
S WangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Y TongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Beijing University of Chemical Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a member of the dibenzyl isoquinoline alkaloid family, cepharathine is an alkaloid from the traditional Chinese medicine cepharathine, which is mainly used for treatment of leukopenia and other diseases. Recent studies of the inhibitory effect of cepharathine against SARS-CoV-2 have attracted widespread attention and aroused heated discussion. As the original discoverer of the anti-SARS-CoV-2 activity of cepharanthine, here we briefly summarize the discovery of cepharanthine and review important progress in relevant studies concerning the discovery and validation of anti-SARS-CoV-2 activity of cepharathine, its antiviral mechanisms and clinical trials of its applications in COVID-19 therapy.

Indexed as

BenzylisoquinolinesCOVID-19Antiviral AgentsBenzodioxolesHumansSARS-CoV-2Antiviral AgentsBenzodioxolesBenzylisoquinolinescepharanthinecepharanthineresearch progressSARS-CoV-2

Identifiers

PMID35790449
PMCPMC9257352
OpenAlexW4283837475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.